Home / Life Sciences

Legal News

Innovative Medicines Initiative to help advance regulatory science

Copyright © 2025 LexisNexis

Published on: 30 March 2020

Published by LNB News

LNB News 30/03/2020

Document Information

Issue Date: 30 March 2020

Published Date: 30 March 2020

Jurisdiction(s): United Kingdom

Article summary

The Innovative Medicines Initiative (IMI) has recently attended the regulatory science summit with the European Medicines Agency and the US Food and Drug Administration. The aim of the summit was ‘to identify scientific gaps that could be addressed collaboratively within a public-private partnership such as IMI, and to ensure that potential IMI projects would deliver tangible results that are relevant from a regulatory perspective to maximise their impact on drug development and on the delivery of innovative products to patients’. Attendees at the summit stated that ‘unblocking the regulatory challenges surrounding advanced therapies and digital technologies could be game-changing for all players’.

Popular documents

Late payment penalties—inheritance tax

Late payment penalties—inheritance taxWhile interest often accrues on overdue tax, the late payment of certain taxes may also attract a penalty. For information on the interest accruing on overdue tax, see Practice Notes: IHT—payment deadlines on death—Interest on IHT and Interest on late paid

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal

If a beneficiary signs a deed of disclaimer of their share of an estate and the estate pays their legal fees, will that count as a PET against their estate?A disclaimer is the refusal of a gift prior to acceptance. The refusal of the gift must take place before the beneficiary accepts any benefit

Can shares in a limited company that have not been paid-up at all be cancelled?

Can shares in a limited company that have not been paid-up at all be cancelled?A limited company having a share capital may not alter that share capital, except in the ways listed in section 617 of the Companies Act 2006 (CA 2006). Shares in a company cannot simply be cancelled without following an

Template for regulatory references given by SMCR firms and disclosure requirements

Template for regulatory references given by SMCR firms and disclosure requirements[Insert addressee details]Dear [insert name][It is our understanding that [insert name of prospective employee] [was an employee of yours between the dates of [insert dates as appropriate] OR is a current employee of